Digirad Introduces New Mobile Gamma Camera; Cardius-1M Features Upgradeable Platform That Expands Physician Imaging Options
[ Back ]   [ More News ]   [ Home ]
Digirad Introduces New Mobile Gamma Camera; Cardius-1M Features Upgradeable Platform That Expands Physician Imaging Options

SAN DIEGO—(BUSINESS WIRE)—June 18, 2004— Digirad Corp. (Nasdaq: DRAD), a leader in solid-state imaging, today announced the introduction of its Cardius(TM)-1M system, which it believes represents a significant advance in nuclear cardiac imaging by offering physicians greater flexibility through an upgradeable mobile platform that is expandable with their evolving practice needs.

The Cardius(TM)-1M system is a mobile, solid-state nuclear gamma camera with a single detector that is dedicated exclusively to cardiac imaging. The mobility of the Cardius-1M imager permits physicians to move the imager to multiple office locations, thereby bringing imaging closer to the patient with a single asset. The mobility of the imaging system also permits the delivery of cardiac imaging procedures in both the physician office and hospital setting. Digirad believes that the Cardius-1M imaging system produces high-quality images on a versatile platform despite the rigors of a mobile environment.

The Cardius-1M system is designed for compatibility with other Cardius series imagers, enabling customers to potentially upgrade to new solid-state technology enhancements as they become available. The Cardius-1M can be upgraded to a Cardius-2, Digirad's stationary, dual-head system, should practice growth warrant a higher throughput system.

"We believe that Cardius-1M is an exciting new mobile product that allows customers to purchase a camera that satisfies their imaging needs today yet is flexible to accommodate practice growth in the future," said David Sheehan, president and chief executive officer of Digirad. "We believe that the ability to upgrade the system will be valuable for those physicians who are just starting out or who cannot yet justify the additional cost associated with a dual-head camera. We are very excited about the option flexibility this platform offers."

The Cardius-1M system is comprised of a solid-state nuclear gamma camera, an upright imaging chair, and an acquisition/processing station. The imager is also equipped with Digirad's proprietary third-generation Solidium(TM) solid-state detector. In addition to being upgradeable to a Cardius-2 through the purchase of Digirad's DualPak(TM) Upgrade Kit, the Cardius-1M system is light weight and offers a small footprint, which allows it to fit into a 7'x8' space without the need for room renovations. Digirad believes that the upright and open architecture of the patient chair used with the Cardius-1M system can increase patient comfort and reduce the incidence of claustrophobia.

About Digirad

Digirad Corp. develops, manufactures and markets solid-state, digital gamma cameras to hospitals, imaging centers and physician offices. Digirad offers a comprehensive line of solid-state nuclear gamma cameras that can be used for the detection of many medical conditions including cardiovascular disease. Digirad believes that these imaging systems produce a high-quality image, and due to their lightweight and compact design, fit easily into small office spaces.

Through its wholly-owned subsidiaries, Digirad Imaging Solutions and Digirad Imaging Systems, Digirad also offers a comprehensive and mobile imaging leasing and services program for physicians who wish to perform nuclear cardiology procedures in their offices but do not have the patient volume, capital or resources to justify purchasing a gamma camera. Digirad Corp., Digirad Imaging Solutions and Digirad Imaging Systems have headquarters in San Diego. For more information, visit www.digirad.com.

Cautionary Language Regarding Forward-Looking Statements

Digirad cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Forward-looking statements give expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. The inclusion of forward-looking statements should not be regarded as a representation by Digirad that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Digirad's business, including, without limitation: the degree to which Digirad's imaging systems and services will be accepted by physicians and hospitals; Digirad's ability to compete against large, well-established competitors with significantly greater resources; any unforeseen changes in domestic and international legislation, regulation or coverage and reimbursement policies of third-party payors; Digirad's ability to timely develop new products and product enhancements that are accepted by the market; any technical problems that may develop with respect to Digirad's imaging systems or any supply problems or price fluctuations that may affect Digirad's third-party suppliers; the ability of Digirad to effectively market, sale and distribute its imaging systems; Digirad's ability to retain and attract key executives, qualified managers, engineers and imaging technologists; Digirad's ability to manage risks relating to product liability, product recalls, property damage and personal injury with respects to its imaging systems; Digirad's reliance on a limited number of customers for its products and imaging services; Digirad's ability to raise additional funds for its operations in the future; Digirad's compliance with extensive product regulations, licensure and reporting requirements of the Food and Drug Administration and other state and federal agencies; Digirad's ability to protect its intellectual property and proprietary technology through patents and other means; Digirad's ability to respond to product liability or warranty claims; and other risks detailed in Digirad's Securities and Exchange Commission filings, including its Prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the Securities and Exchange Commission on June 10, 2004.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Digirad undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Digirad(R) and Digirad Imaging Solutions(R) are registered trademarks of Digirad Corp.

Cardius(TM), Solidium(TM) and DualPak(TM)are trademarks of Digirad Corp.

Digirad Corp., San Diego
Todd Clyde, 858-726-1600
Fax: 858-726-1701

Email Contact